[{"orgOrder":0,"company":"TeraImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"TI-168","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"TeraImmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"TeraImmune \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TeraImmune \/ Not Applicable"},{"orgOrder":0,"company":"TeraImmune","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"TI-168","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"TeraImmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"TeraImmune \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"5","companyTruncated":"TeraImmune \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"TeraImmune","sponsor":"Baudax Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"TI-168","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"TeraImmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"TeraImmune \/ Baudax Bio","highestDevelopmentStatusID":"5","companyTruncated":"TeraImmune \/ Baudax Bio"}]

Find Clinical Drug Pipeline Developments & Deals by TeraImmune

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The merger adds TeraImmune’s TI-168 asset to the Baudax portfolio, a promising next-generation, autologous FVIII TCR-Treg cell therapy candidate to eliminate clotting factor VIII (FVIII) inhibitors in Hemophilia A patients.

                          Brand Name : TI-168

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 30, 2023

                          Lead Product(s) : TI-168

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : Baudax Bio

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Under the agreement, TeraImmune continues to develop cGMP-compliant manufacturing protocol for its lead candidate, TI-168, and clinical laboratory manuals designed to provide relevant tactical support for the upcoming clinical trial.

                          Brand Name : TI-168

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 04, 2023

                          Lead Product(s) : TI-168

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : National Institute of Allergy and Infectious Diseases

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : TI-168 is a next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitor. The primary objectives are to evaluate the safety and feasibility of TI-168 and determine the maximum tolera...

                          Brand Name : TI-168

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          October 11, 2022

                          Lead Product(s) : TI-168

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank